NextTechs: Biomedical Technology Challenges

EDITORIAL: Obama's ineffective executive decision - Washington Times

CBS News

EDITORIAL: Obama's ineffective executive decision Washington Times Administration transparency plans for stimulus spending proved to be more punch line than punch. The Recovery.org Web site, which is supposed to track the ... Obama Pledges to Put More Americans Back to Work President turns to job creation Thanks for the November Jobs Report?  - -

Dem leaders to members: Start bragging about accomplishments - The Hill

True/Slant

Dem leaders to members: Start bragging about accomplishments The Hill They are also noting items that haven't been forgotten but are more controversial: the $787 billion stimulus and the healthcare bill passed by the House. ... Afghan surge shows fissures between Hill and White House Of government and 10.2 percent unemployment

The costs of Obama's ambitions - Washington Post

The costs of Obama's ambitions Washington Post Bailouts for banks and automakers and a huge stimulus package to short-circuit the recession. Iraq? Set a date for withdrawal promptly. Health care? ...

Direct Flow Medical, Inc.: Series C $40M

Direct Flow Medical (Santa Rosa, CA) a development-stage medical device company focused on a percutaneous aortic tissue valve prosthesis, closed a $40M Series C financing. Participants include Johnson & Johnson Development Corp., Foundation Medical Partners, VantagePoint Venture Partners, ePlanet Ventures, EDF Ventures, New Leaf Venture Partners and Spray Venture Partners.

Molecular Detection, Inc.: Series C $3.3M

Molecular Detection (Wayne, PA) a development-stage molecular diagnostics company focused on reat-time PCR of MRSA detection, closed a $3.3M Series C financing. Participants include MentorTech Ventures, Ben Franklin Technology Partners, Robin Hood Ventures and the Mid-Atlantic Angel Group.

ThermalTherapeutic Systems, Inc.: Series A $2.7M

ThermalTherapeutic Systems (Pittsburgh, PA) a development stage device company focused on portable hyperthermic perfusion system for temperature control of the thoracic or peritoneal cavity, closed a $2.7M Serie A financing. Participants include Originate Ventures, Pittsburgh Life Sciences Greenhouse and Innovation Works.

Virdante Pharmaceuticals, Inc.: Series A $30M

Virdante Pharmaceuticals (Cambridge, MA) a development-stage biopharmaceutical company focused on increasing potency of plasma-derived intravenous immune globulin for the treatment of inflammation and autoimmune disease, closed a $30M Series A financing. Participants include Thomas, McNerney & Partners, Osage Partners, Clarus Ventures, Venrock, MedImmune Ventures and Biogen Idec New Ventures.

Quinnova Pharmaceuticals, Inc.: Series B $17.4M

Quinnova Pharmaceuticals (Newtown, PA) a commercial-stage specialty biopharma company focused on dermatological drug reformulations and foam delivery systems, closed a $17.4M Series B financing. Participants include Safeguard Scientifics, Thomas, McNerney & Partners, H.I.G. Ventures.